TY  - JOUR
AU  - Pfeil, Julia
AU  - Hoenig, Merle C.
AU  - Doering, Elena
AU  - van Eimeren, Thilo
AU  - Drzezga, Alexander
AU  - Bischof, Gerard Nisal
AU  - Initiative, Alzheimer's Disease Neuroimaging
TI  - Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease
JO  - Neurobiology of aging
VL  - 106
SN  - 0197-4580
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - FZJ-2021-05942
SP  - 119 - 129
PY  - 2021
AB  - Although beta-amyloid (Aβ) positivity has shown to be associated with higher risk of progression to Alzheimer's disease (AD) in mild cognitive impairment (MCI), information on the time to conversion to manifest dementia cannot be readily deduced from this binary classification. Here, we assessed if regional patterns of Aβ deposition measured with 18F-florbetapir may serve as biomarker for progression risk in Aβ-positive cognitively normal (CN) and MCI patients, including clinical follow-up data and cerebrospinal fluid (CSF) biomarkers. Voxel-wise group comparisons between age and sex-matched Aβ-positive groups (i.e., CN-stables [n = 38] vs. CN-to-MCI/AD progressors [n = 38], MCI-stables [n = 104] versus MCI-to-AD progressors [n = 104]) revealed higher Aβ burden in precuneus, subcortical, and parietal regions in CN-to-MCI/AD progressors and cingulate, temporal, and frontal regions in MCI-to-AD progressors. Importantly, these regional patterns predicted progression to advanced stages on the AD spectrum in the short and the long-term beyond global Aβ burden and CSF biomarkers. These results suggest that distinct regional patterns of Aβ burden are a valuable biomarker for risk of disease progression in CN and MCI.
LB  - PUB:(DE-HGF)16
C6  - 34284259
UR  - <Go to ISI:>//WOS:000691900600011
DO  - DOI:10.1016/j.neurobiolaging.2021.06.014
UR  - https://juser.fz-juelich.de/record/904372
ER  -